← Therapy pipeline
Investigational · Obesity development

Taldefgrobep alfa

BHV-2000 · BHV2000-202 · Biohaven

A myostatin/activin-pathway inhibitor being studied for weight reduction and body composition.

MyostatinActivin
Other study areas
Body composition
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 2Updated as of November 2026
SponsorBiohaven
TargetsMyostatin + Activin
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Results availability

No numerical results shown

No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.

02 / How it works

Mechanism at a glance

GLP-1GLP-1—
GIPGIP—
GCGglucagon—
AMYamylin—
OTHOther targetsTargeted

Body-composition and other targets appear alongside hormone pathways in this overview.

Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

Injection
Phase 2Phase 2 ongoing; GLP-1 combination amendment planned; topline expected H2 2027
Milestone → next

Latest: Biohaven reported on October 29, 2026, that the Phase 2 obesity study remains ongoing and is being amended to assess combination treatment with a GLP-1-based therapy.

Next: Sponsor expects monotherapy and combination topline results in the second half of 2027; the combination amendment remains in progress.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 2 studies1 record

Phase 2b

REV-OBESITY · BHV2000-202

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Phase 2 study in overweight adults and adults with obesity. Biohaven’s October 29 update describes a GLP-1 combination amendment in progress and H2 2027 topline timing; no obesity efficacy result was disclosed.